S&P 500NASDAQ-100

Vertex Pharmaceuticals (VRTX) — 10-Year DCF Projection Model

Free stock research tool. Build a 10-year revenue, earnings (EPS), and free cash flow forecast for Vertex Pharmaceuticals (VRTX) stock, a company in the Health Care (Biotechnology) sector. Pulls audited SEC EDGAR XBRL financials, triangulates Wall Street analyst consensus across Yahoo Finance, NASDAQ, and StockAnalysis, and overlays AI-clustered news + social event probabilities directly onto projected EPS. For equity research — not personal budgeting or accounting.

Build VRTX projection model →Browse all stocks

Vertex Pharmaceuticals at a glance

Ticker
VRTX
Company
Vertex Pharmaceuticals
Sector
Health Care
Sub-industry
Biotechnology
Headquarters
Boston, Massachusetts
Founded
1989
Added to S&P 500
2013-09-23
Index membership
S&P 500, NASDAQ-100

What you'll see in your VRTX model

  • 10 years of audited historical financials for Vertex Pharmaceuticals, sourced directly from the SEC's EDGAR XBRL filings (10-K and 10-Q).
  • Triangulated Wall Street consensus for VRTX's forward revenue, EBITDA, and EPS across Yahoo Finance, NASDAQ, and StockAnalysis with cross-source dispersion (σ).
  • AI Event Factors: top-10 news/social themes for VRTX with probability sliders and live EPS impact.
  • Sensitivity tables and Excel export for every assumption.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals (NYSE/NASDAQ: VRTX) was founded in 1989 and is headquartered in Boston, Massachusetts. The company operates in the Health Care sector (Biotechnology sub-industry) and is a constituent of the S&P 500 and NASDAQ-100. Our projection model builds a clean discounted-cash-flow view of Vertex Pharmaceuticals in roughly five seconds and lets you adjust every assumption to test your own thesis.